KAINOS Laboratories, Inc. (4556.T) Income Statement Analysis – Financial Results

About KAINOS Laboratories, Inc.

KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.